Severe obesity is already a significant problem for many children, especially since obese children often become obese adults.

Among patients receiving persistent medication at one year, 61% of patients prescribed semaglutide for obesity achieved at ...

These RCT findings support safety and efficacy in 6 to 12 year olds, but there are many unanswered questions, one expert says ...

Currently, there are no approved medications for treating nonmonogenic, nonsyndromic obesity in children under 12. While ...

The study concentrates on the FDA-approved injectable medications semaglutide and liraglutide. A study conducted by the ...

Liraglutide treatment significantly lowers BMI in obese children aged 6 to <12, but gastrointestinal side effects prompt the ...

The Clinical Trials Arena team investigates assets in infectious diseases, metabolic disorders, oncology and ophthalmology.

Children who used the weight loss drug liraglutide in a late-stage trial lost significantly more weight than children who got ...

For patients with obesity receiving semaglutide or liraglutide, weight reduction at one year is associated with medication ...

Liraglutide has been found to safely reduce BMI in children aged 6 to under 12, offering a potential new treatment for pediatric obesity. The obesity medication liraglutide was found to be safe and ...

Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...

In the heavyweight title match between weight loss meds, we have ourselves a victor.In the battle between Novo Nordisk’s ...